Compare Roundhill Magnificent Seven ETF (MAGS) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Roundhill Magnificent Seven ETF trades at $73.73 (market cap $5.78B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 4.4× Roundhill Magnificent Seven ETF's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Roundhill Magnificent Seven ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Magnificent Seven ETF for 36 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| MAGS | RPRX | |
|---|---|---|
Market Cap | $5.78B | $25.27B |
Volume | 4,410,665 | 3,671,183 |
Sector | Sector/Thematic | Health |
52-Week High | $73.90 | $63.96 |
52-Week Low | $55.39 | $35.44 |
Typical Hold Time | 36 Days | 1 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS trades at $73.03, down 0.9% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF provides equal-weighted exposure to the Magnificent Seven tech stocks, though 2026 performance has been muted with a 2% year-to-date gain as the group faces increased competition and AI spending pressures. Recent news highlights both the long-term AI growth theme and near-term underperformance versus the broader market.
The outlook hinges on AI-driven earnings growth from its mega-cap holdings, but concentration risk and shifting investor sentiment pose challenges. Upside potential exists if the Magnificent Seven reassert leadership, while downside risks include prolonged sector rotation and margin compression from heavy capital expenditure.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
